Oxford BioMedica has 20 years of experience in the field of gene and cell therapy and we were the first organisation to treat humans in vivo with lentiviral based vectors. Today, we have built our LentiVector® platform of exclusive cutting-edge technologies and capabilities with which we design, develop and produce gene and cell-based medicines for ourselves and for our partners.
We already have product-related partnerships with Novartis, Immune Design, Orchard Therapeutics, licensed products and technology rights to Sanofi, technology rights to GSK, and an R&D collaboration with Green Cross LabCell.
We have our own proprietary pipeline of gene and cell therapy products addressing neurodegenerative and ocular diseases and a range of cancers, for which there are either no treatments or where therapy remains inadequate.
